References
- Verduin CM, Hol C, Fleer A, van Dijk H, van Belkum A. Moraxella catarrhalis: from emerging to established pathogen. Clin Microbiol Rev 2002; 15: 125–144.
- Karlowsky JA, Thornsberry C, Critchley IA, et al. Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000–2001 and 2001–2002 TRUST studies in the United States. Antimicrob Agents Chemother 2003; 47: 1790–1797.
- Doern GV and the Alexander Project Collaborative Group. Antimicrobial resistance among lower respiratory tract isolates of Haemophilus influenzae: results of a 1992–1993 Western Europe and USA collaborative surveillance study. J Antimicrob Chemother 1996; 38 (Suppl. A): 59–69.
- Thornsberry C, Jones ME, Hickey ML, Mauriz Y, Kahn J, and Sahm DF. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997–1998. J Antimicrob Chemother 1999; 44: 749–759.
- Inoue M, Lee NY, Hong SW, Lee, K, Felmingham D. PROTEKT 1999–2000: a multi-centre study of the antibiotic susceptibility of respiratory tract pathogens in Hong Kong, Japan and South Korea. Int J Antimicrob Agents 2004; 23: 44–51.
- Hoban D, Felmingham D. The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections. J Antimicrob Chemother 2002; 50 (Suppl. S1): 49–59.